SUN 1334H manufacturers
- SUN 1334H
-
-
2026-07-16
- CAS:607736-84-5
- Purity:
- Supply Ability: 10g
- SUN 1334H
-
-
2026-07-15
- CAS:607736-84-5
- Purity:
- Supply Ability: 10g
- SUN 1334H
-
-
2025-08-22
- CAS:607736-84-5
- Purity:
- Supply Ability: 10g
|
| | SUN 1334H Basic information |
| Product Name: | SUN 1334H | | Synonyms: | SUN 1334H;2-?[[(2E)?-?4-?[4-?[bis(4-?Fluorophenyl)?methyl]?-?1-?piperazinyl]?-?2-?buten-?1-?yl]?oxy]?-acetic acid hydrochloride | | CAS: | 607736-84-5 | | MF: | C23H27ClF2N2O3 | | MW: | 452.93 | | EINECS: | | | Product Categories: | | | Mol File: | 607736-84-5.mol |  |
| | SUN 1334H Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | color | Light yellow to yellow |
| | SUN 1334H Usage And Synthesis |
| Uses | SUN 1334H is a potent, orally active, highly selective H1 receptor antagonist, with Ki of 9.7 nM. | | in vivo | SUN-1334H potently inhibits histamine-induced bronchospasm over 24 hours following oral administration and completely suppresses histamine-induced skin wheal in beagle dogs and ovalbumin-induced rhinitis in guinea pigs[1]. In skin allergy models, SUN-1334H shows potent reduction of passive and active cutaneous anaphylactic reactions. In central nervous system side effects models, SUN-1334H, desloratadine and fexofenadine are devoid of any significant effects[2]. | | IC 50 | H1 Receptor | | References | [1] Mandhane SN, et al. Preclinical efficacy and safety pharmacology of SUN-1334H, a potent orally active antihistamine agent. Drugs R D. 2008;9(2):93-112. DOI:10.2165/00126839-200809020-00004
[2] Mandhane SN, et al. Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H. Int Arch Allergy Immunol. 2010;151(1):56-69. DOI:10.1159/000232571 |
| | SUN 1334H Preparation Products And Raw materials |
|